Navigation Links
IDM Pharma Reports Third Quarter 2007 Financial Results
Date:11/8/2007

IRVINE, Calif., Nov. 8 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced its financial results for the quarter and nine months ended September 30, 2007. Financial information presented represents the consolidated results of IDM Pharma and its subsidiary, IDM S.A.

Cash and cash equivalents totaled $33.2 million as of September 30, 2007 compared to $37.3 million on June 30, 2007 and $10.2 million on December 31, 2006. The Company's net cash outflow from operations and investment activities for the quarter and nine months ended September 30, 2007, which excludes cash received from financing activities and the effect of exchange rates, was approximately $5.1 million and $14.3 million, respectively.

"During the third quarter we announced our intention to collect additional survival data from the L-MTP-PE Phase 3 trial and submit an amendment to the NDA in the first quarter of 2008," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "In addition, we announced the appointment of Jeff Sherman as our chief medical officer who brings valuable expertise to the management team as we work through the regulatory approval process for L-MTP-PE in the U.S. and Europe, and as we develop our oncology pipeline."

Quarter Ended September 30, 2007

Total revenues in the third quarter of 2007 were $3.1 million compared to total revenues of $3.0 million for the quarter ended September 30, 2006. Substantially all of the revenues for both periods were derived from the Company's collaboration agreement with sanofi-aventis. The $0.1 million increase in revenues in the 2007 period was due to an increase in development costs related to UVIDEM clinical trials, which are reimbur
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... Demand Response Management Systems is a crucial peak ... imbalance between energy supply and demand. With the help ... (due to increasing pressure on the grid) and replaced ... residential appliances and thermostats for load reduction. , ... and with government mandates and benefits for energy efficiency ...
(Date:7/12/2014)... 12, 2014 Tylenol lawsuits ( ... move forward in the federal multidistrict litigation underway ... Bernstein Liebhard LLP reports. According to a filing ... F. Stengel has ordered the deposition of a ... found that the witness’s testimony concerning the marketing ...
(Date:7/12/2014)... (HealthDay News) -- Burn injuries increase in the summer as ... burn experts. Among those most vulnerable to these seasonal fire ... and often get burned by putting their hands on the ... the burn unit at Loyola University Medical Center in Maywood, ... adage of ,When you play with fire, you get burned, ...
(Date:7/12/2014)... July 12, 2014 “After my mom’s stroke, she ... a stroke and loss the use of his left side. Eating ... a way to help people like them enjoy eating again,” said ... prototype for the PATRICIA CAROL HALL PLATE (P C H PLATE). ... a more ergonomic way to eat for individuals who suffer from ...
(Date:7/12/2014)... July 12, 2014 With prom shopping ... manufacturer and retailer, is ready to showcase its new ... new collection of evening dresses in its online shop. ... 67% off) for these elegant gowns. According to the ... end on July 26, 2014. , He says, ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2
... clinical trial of the experimental drug dimebon (latrepirdine) in people ... cognition. That is the conclusion of a study published ... "This is the first clinical trial that has focused ... disease," said University of Rochester Medical Center neurologist Karl Kieburtz, ...
... with use, but other factors may contribute, experts say , ... treat glaucoma appear to outlive those who don,t treat the ... reduced risk for premature death stems from the glaucoma drugs ... access to health care remains unclear. , Use of glaucoma ...
... residue may give rise to new pollutants indoors, chemists ... smoke residue found on indoor surfaces -- so-called "third-hand ... new, potentially cancer-causing substances, research suggests. , Details about ... what health concerns it might create remain unclear, however, ...
... BOSTON , Feb. 8 The National Patient ... on March 7, 2010 , in a concerted effort ... of health care, and strengthen alliances between patients, families and ... During the week, participating hospitals and healthcare systems will plan ...
... , Feb. 8 Independence Blue Cross (IBC) today ... newly created role of senior vice president of marketing services. He ... executive, Linda M. Taylor . , In this new ... care consumers better manage their care and will also head product ...
... , Feb. 8 SpectraCell Laboratories announced that ... D.C. to its scientific staff as Director of Clinical Nutrition ... national basis and consult with clients on the implementation of ... is a long-time client of SpectraCell, using their micronutrient testing ...
Cached Medicine News:Health News:Drug shows promise for Huntington's disease 2Health News:Glaucoma Drugs May Play Role in Longer Life 2Health News:Glaucoma Drugs May Play Role in Longer Life 3Health News:'Third-Hand Smoke' Could Be Troublesome, Too 2Health News:'Third-Hand Smoke' Could Be Troublesome, Too 3Health News:National Patient Safety Foundation Leads Nationwide Effort to Promote Patient Safety 2Health News:Independence Blue Cross Names John Janney to Newly Created Position: Senior Vice President Marketing Services 2Health News:Independence Blue Cross Names John Janney to Newly Created Position: Senior Vice President Marketing Services 3Health News:Dr. Ron Grabowski Named Director of Clinical Nutrition and Education for SpectraCell Laboratories 2Health News:Dr. Ron Grabowski Named Director of Clinical Nutrition and Education for SpectraCell Laboratories 3
(Date:7/10/2014)... Yesterday, former Congressman Patrick Kennedy ... facility. Rep. Kennedy and Dick Moberg ... research in neurological disease and treatment. ... Garen Staglin , created One Mind, a ... that will radically accelerate the development and implementation ...
(Date:7/10/2014)... TUCSON, Ariz. , July 10, 2014   ... Roche  Group, today announced it has entered into an ... , which operates as EMD Serono in ... , to collaborate with Merck KGaA,s biopharmaceutical division ... (CDx) for an undisclosed target using Ventana,s proprietary diagnostic ...
(Date:7/10/2014)... 10, 2014 CVS Caremark Corporation (NYSE: ... approved a quarterly dividend of $0.275 (27.5 cents) per share ... August 1, 2014, to holders of record on July 21, ... Caremark is dedicated to helping people on their path to ... the United States . Through the company,s more ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... , ALLEGAN, Mich. , Jan. 27 ... Directors declared a quarterly dividend of $0.0625 per ... of record on February 26, 2010 . , Perrigo ... and distributes over-the-counter (OTC) and generic prescription pharmaceuticals, nutritional products, ...
... , NEW YORK , Jan. ... Investments, Inc. (NYSE Amex: MGT ), and an industry ... analysis software which assists radiologists in the early detection of ... received a further request for Additional Information (AI) letter from ...
Cached Medicine Technology:Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance 2Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance 3
InterVascular HemaPatch product line offers the vascular surgeon a range of collagen coated patches in a range of larger sizes angioplasty, or profundaplasty procedures without suture hole bleeding. ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
The D-Stat Radial hemostat band utilizes a compression band together with the active haemostatic material of the D-Stat to control surface bleeding....
Medicine Products: